Skip to content
Menu

Eupraxia Pharmaceuticals Inc. EPRX

Full chart Compare
Set alert

Price alert · EPRX

All alert types
6.12 USD -0.09 (-1.45%)

Regular-session close

6.12 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

6.09 Day range 6.57
5.63 52-week range 9.32
YTD
-18.94%
1 year
-1.29%

5D -1.66 (-20.05%)

78WedThuFriMonTue6.62
Market cap
411.68M
EPS (ttm)
-1.07
Shares out
35.62M
YTD return
-18.94%
1-year return
-1.29%
50-day average
3.00
200-day average
2.78
Volume
736.43K
Avg volume
732.14K
Open
6.31
Previous close
6.21
Day's range
6.09 – 6.57
52-week range
5.63 – 9.32
Beta
1.23

Key statistics

Enterprise value
92.53M
Price / book
38.15
Free cash flow
-14.62M
Total cash
23.32M
Total debt
4.66M
Return on equity
-314.41%

Fundamental scorecard

3 of 25 checks passed on EPRX’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
EPRX Revenue — quarterly 0
EPRX Net income — quarterly -15.25M
EPRX EPS — quarterly -0.23

Upgrades / downgrades

EPRX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024Rodman & Renshawinit—Buy

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

Your note

Sign in to keep a note on EPRX — it syncs with the Stock Master app.

Institution ownership

EPRX institution ownership
Holder% heldSharesValueReported
Scotia Capital Inc.3.92%1,396,2814.31MSep 29, 2024
Royal Bank of Canada0.76%271,287838.28KSep 29, 2024
Bank of Montreal /CAN/0.14%49,250152.18KSep 29, 2024
Goldman Sachs Group Inc0.10%34,500106.60KSep 29, 2024
UBS Group AG0.09%33,000101.97KSep 29, 2024
180 Wealth Advisors, LLC0.04%13,00040.17KSep 29, 2024